Immuno-oncology/Tyrosine Kinase Inhibitor Combination Therapies for the Treatment of Advanced Renal Cell Carcinoma: Which of Your Patients May Benefit from Their Use in the First line Setting?

FACULTY

PROGRAM CHAIR

Brian Rini, MD, FASCO
Professor of Medicine
Chief of Clinical Trials
Vanderbilt-Ingram Cancer Center
Nashville, TN

FACULTY PRESENTERS

Daniel M. Geynisman, MD
Associate Professor, Hematology/Oncology
Fox Chase Cancer Center
Philadelphia, PA

PROGRAM OVERVIEW

This series of TeleECHO activities will discuss the management of patients with advanced and/or metastatic (m) renal cell carcinoma (RCC) and therapeutic options available in the first line setting.

TARGET AUDIENCE

This activity is intended for US-based community oncologists involved in the management of patients with RCC.

LEARNING OBJECTIVES

Upon the completion of this program, attendees should be able to:

  • Evaluate evidence from clinical trials assessing novel combination IO/TKI therapies for the treatment of patients with advanced and/or mRCC in the first line setting
  • Select patients with advanced and/or mRCC that are most likely to benefit from IO/TKI combination therapies in the first line setting
  • Devise strategies to manage the immune-related adverse events (irAEs) and treatment-related adverse events (trAEs) associated IO/TKI combination therapies used in the first line setting for patients with advanced and/or mRCC

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring virtual activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring virtual activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with advanced and/or metastatic RCC.
CNE Credits: 1.0 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Faculty Member Disclosures
Brian Rini, MD Discloses that he has done consultant work for BMS, Pfizer, GNE/Roche, Aveo, Synthorx, Compugen, and Merck & Co.
Daniel Geynisman, MD Discloses that he has received consultant fees from Exelixis, Astellas, Seattle Genetics, Merck & Co., and BMS.

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.

Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner
The reviewer of this activity has nothing to disclose.

Staff Planners and Managers

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Marcello Morgan, MD, MPH, Medical Director for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Lisa Crenshaw, Senior Program Manager for Med Learning Group, has nothing to disclose.
Daniel Dasilva, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
Morgan Kravarik, Associate Program Manager for Med Learning Group, has nothing to disclose.
Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring virtual activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the web-based enduring activity.
  3. Submit the evaluation form to Med Learning Group.

You will receive your certificate upon completion.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com.

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to the live event at info@medlearninggroup.com

RELEASE DATE: January 28, 2022

EXPIRATION DATE: January 28, 2023

Copyright © 2022 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

Scroll to Top

A Special Thank You to All HCPs

Med Learning Group sends its heartful gratitude to all healthcare professionals giving their all, 24/7, during this pandemic, despite the great risks they face. We cannot thank you enough for your courage and selfless service.

Connecting you with our personalized approach to continuing Medical Education

The Linking Approach to Education from Gap Analysis to Outcomes

Med Learning Group, a division of Ultimate Medical Academy, is a full-service accredited medical education company with commendation. Med Learning Group focuses on developing and implementing continuing education that improves healthcare practitioners’ ability to provide optimal care to their patients. Our goal is to provide high-quality education that is designed to deliver the highest level of outcomes for not only the practitioner, but also the patient. Med Learning Group has expertise in developing both live and online activities that are innovative, case-based, interactive and patient-centric in nature.

Med Learning Group has expertise in developing both live and online activities that are innovative, case-based, interactive and patient-centric in nature, and we focus on applying adult learning theory and principles to our programs. Even more importantly, we understand the nuances of our target audiences and design programs with a grounded understanding of how to educate both specialty audiences and general practitioners.